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Toward genome editing in X-linked
RP—development of a mouse model with
specific treatment relevant features
J. SCHLEGEL1, J. HOFFMANN, D. R €OLL2, B. M€ULLER, S. G€UNTHER, W. ZHANG, A. JANISE,
C. V €OSSING, B F€UHLER, J. NEIDHARDT, H. KHANNA, B. LORENZ, and K. STIEGER
GIESSEN, BAD NAUHEIM, AND OLDENBURG, GERMANY ANDWORCESTER, MASSACHUSETTS
Genome editing represents a powerful tool to treat inherited disorders. Highly spe-
cific endonucleases induce a DNA double strand break near the mutant site, which
is subsequently repaired by cellular DNA repair mechanisms that involve the pres-
ence of a wild type template DNA. In vivo applications of this strategy are still rare,
in part due to the absence of appropriate animal models carrying human disease
mutations and knowledge of the efficient targeting of endonucleases. Here we
report the generation and characterization of a new mouse model for X-linked reti-
nitis pigmentosa (XLRP) carrying a point mutation in the mutational hotspot exon
ORF15 of the RPGR gene as well as a recognition site for the homing endonuclease
I-SceI. Presence of the genomic modifications was verified at the RNA and protein
levels. The mutant protein was observed at low levels. Optical coherence tomogra-
phy studies revealed a slowly progressive retinal degeneration with photoreceptor
loss starting at 9 months of age, paralleling the onset of functional deficits as seen in
the electroretinogram. Early changes to the outer retinal bands can be used as bio-
marker during treatment applications. We further show for the first time efficient tar-
geting using the I-SceI enzyme at the genomic locus in a proof of concept in
photoreceptors following adeno-associated virus mediated gene transfer in vivo.
Taken together, our studies not only provide a human-XLRP disease model but also
act as a platform to design genome editing technology for retinal degenerative dis-
eases using the currently available endonucleases. (Translational Research 2019;
203:5772)
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At A Glance Commentary
Schlegel J, et al.
Background
Genome editing in the retina is currently at the
height of debate with regard to clinical translation,
yet important aspects of the in vivo application are
still poorly understood, in part due to the lack of
animal models with human-like mutations.
Translational Significance
Our mouse model contains a human-like mutation
in the RPGR-ORF15 gene, in which mutations in
human cause XLRP. Due to its degenerative phe-
notype and the presence of an I-SceI restriction
site, this mouse model is well suited to study the
efficacy of all classes of endonucleases and to
characterize the efficacy of therapeutic applica-
tions in retinal neurons in vivo.
INTRODUCTION
Retinitis pigmentosa (RP) is a group of heterogeneous
disorders affecting primarily rod photoreceptors account-
ing for about 3 million patients worldwide. Mutations in
the gene encoding the retinitis pigmentosa GTPase regu-
lator (RPGR) are a major cause of RP in humans.1 They
account for 15%20% of sporadic RP cases and up to
80% of all X-linked RP cases.2,3 Patients typically suffer
from early night-blindness with reduction of the visual
field and reduced visual acuity, indicating an implication
of both rods and cones in the pathology.4 Optical coher-
ence tomography (OCT) analyses show rapid loss of
outer retinal structures that progresses over time.5
The RPGR gene consists of 19 exons and encodes
multiple alternatively spliced isoforms. Two major
RPGR isoforms RPGRconst (encoded by 19 exons) and
RPGRORF15 (terminates within intron 15) have been
reported, the latter being uniquely expressed in photo-
receptors.6 Physiologically, both RPGR protein var-
iants are located in the connecting cilium (CC) of the
vertebrate photoreceptor, where they take part in a pro-
tein complex associated with the intraflagellar transport
machinery that facilitates ciliary protein trafficking.7-9
In addition, the RPGRconst protein is also important for
the transport of cargo toward the cilium via prenylation
of the C-terminus by PDE6delta.10
Most of the disease-causing mutations in humans are
found in RPGRORF15. The terminal exon ORF15 (exon
15+ part of intron 15) of the RPGRORF15 isoform is a
mutational hot spot, accounting for >60% of RPGR
mutations.6 This exon consists of extensive purine-rich
repeats and encodes for glycine (G) and glutamic acid
(E) residues. The majority of the exon ORF15 mutations
result in a frameshift due to deletions or duplications.3
Although the mechanism of action of these mutations is
not completely understood, an effect on the isoelectric
point11 or alterations in the post-translational modifica-
tions12,13 of RPGRORF15 have been proposed.
Recently, several groups have shown the therapeutic
effect of delivering the full-length RPGRORF15 with
either wild type exon ORF1514,15 or as a codon opti-
mized version via adeno-associated virus (AAV) vec-
tor mediated gene transfer.16 While production of a
recombinant protein has been shown to restore function
in the dog model of the disease (X linked progressive
retinal atrophy, XLPRA2)15 and in a knock out (KO)
mouse model,14,16 potential drawbacks with this form
of treatment are always related to the artificial control
of transgene expression or the interaction of residual
endogenous protein with the recombinant protein.
In vivo genome editing represents a powerful tool to
circumvent this issue, as it enables the correction of the
disease-causing mutation in the genome, which would
result in restoration of endogenous protein production. It
is based on the cell’s capacity to repair DNA double
strand breaks (DSBs) by either error-prone nonhomolo-
gous end-joining (NHEJ), or in the presence of a template
DNA by homology-directed repair or microhomology-
mediated end-joining.17 Induction of DSB at the target
locus can be performed by specific endonucleases, of
which a comprehensive toolbox exists, that is, homing
endoncleases (HE) such as I-SceI, zinc-finger nucleases,
TALE nucleases, or the CRISPR-Cas system.18 However,
size limitations in AAV vectors generate problems when
TALE nucleases or CRISPR-Cas systems19 are used
together with the appropriate template DNA. Since HEs
have been long considered to be un-programmable, they
were not used to develop therapeutic strategies, even
though their relatively small size and low toxicity render
them an interesting tool. Recent progress in programming
HEs for eukaryotic target loci may overcome this issue.20
Because the cellular DSB repair mechanisms are dif-
ficult to control in vivo and off target toxicity remains a
major issue, current strategies to target exonic muta-
tions in inherited retinal dystrophy genes in vivo are
still comparably risky.18 The absence of appropriate in
vivo model systems to study genome editing in the ret-
ina in detail further complicates that issue. Standard
knock-out models with large deletions or insertions in
the genome do not represent ideal systems to study pre-
cise genome editing. Disease models based on point
mutations are rare and only available for few inherited
retinal dystrophies.21
Since most of the disease causing mutations in X-
linked retinitis pigmentosa (XLRP) are located in the
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RPGR-ORF15 exon and genome editing application
are dependent on realistic animal model systems, the
aim of this study was to develop a mouse model for
XLRP containing a human-like mutation in the ORF15
exon that also contains specific features important for
the development of therapeutic genome editing strate-
gies. These features include a point mutation (deletion)
similar to that in patients, other silent mutations for
screening purposes and the introduction of an I-SceI
recognition site in order to study this enzymes cutting
efficiency in a therapeutically relevant system. Here
we report the generation and characterization of a new
mouse model of XLRP carrying a point mutation in
exon ORF15 of the Rpgr gene and an I-SceI site down-
stream of exon ORF15, and provide evidence for
NHEJ at the RPGR locus following I-SceI expression
in cell culture and in photoreceptors in vivo following
AAV mediated gene transfer.
MATERIALS AND METHODS
Ethics statement. The animals were maintained and
experimental procedures complied in accordance with
the Animal Welfare guidelines of the local German
authorities and the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. The
Institutional Animal Care and Use Committee of the
local government approved all procedures (permission
22/2011 and 79/2016). Surgery and in vivo examina-
tions were performed under anaesthesia and all efforts
were taken to avoid suffering of the animals. Mice
were euthanized by cervical dislocation. Mice were
kept and bred in a 12-hour light and/or dark cycle with
unlimited access to food and water in the animal facil-
ity of the Max-Planck-Institute for Heart and Lung
Research in Bad Nauheim or in the animal facility of
the Institute of Biochemistry at the Justus-Liebig-Uni-
versity Giessen.
Generation of the B6J.Sv129-Rpgrtm1Sti mouse model.
The generation of the targeting vector was done using
the method of homologous recombination by gap
repair.22 A bacterial artificial chromosome BAC plas-
mid (pBACe3.6) containing the genomic locus of Rpgr
was purchased from ImaGene GmbH (Berlin, Ger-
many). A part of the genomic RPGR locus containing
exons 13, Orf14/15, as well as a loxP/FRT flanked
Neomycin cassette for positive selection were recom-
bined via gap repair into the pKOIIV2 plasmid (kindly
provided by Thomas Braun, MPI Bad Nauheim, Ger-
many), already containing a DTA (diphtheria toxin A)
cassette (Fig 1, A). To introduce the 4 mutations, the
Orf15 sequence was cloned into a pL452 plasmid22
and the defined point mutations were integrated via
mutagenesis polymerase chain reaction (PCR). The
mutated target-sequence was cloned into the pKOIIV2
by directed cloning via Sal-I and Sac-II restriction
digestion, thus finalizing the targeting vector.
For homologous recombination in embryonic stem
(ES) cells, the targeting vector was linearized by NotI and
electroporated into male ES cells (C57BL/6/129sv hybrid
cells). Transgenic clones were selected by G418 resis-
tance and screened for correct homologous recombination
by long range PCR using primers binding within the Neo-
mycin sequence [TTCTGAGGGGATCAATTCTCTA-
GAGCTCGC] and outside the recombination site
[AGATCTGACGCCCTCTTCTGGTGTTTCTGAAG]
(Fig 1, A, external sonde eS), and by standard PCR span-
ning 500 bp around the newly introduced XbaI site and
the pathologic frame shift mutation (Fig 1, A, internal
sonde iS) using primers [GGAAATGTAGTAGTG-
GAGCA] and [TTGATCCTCTGATGTGCCTT]. Pres-
ence of the I-SceI site was verified by PCR using primers
[GATAATGAAAGTCAGGAAG] and [GGGTTATT-
GAATATGATCGGAATTGG] (Fig 1, B). Positive
clones were injected into C57BL/6J blastocysts and F1
hybrid offspring was tested for the presence of DNA
changes by PCR as described above. Genomic DNA was
isolated from tail to tip tissue with the DNeasy Tissue Kit
(Qiagen, Hilden, Germany). The neomycin cassette was
deleted from the genome via Cre-recombination of the F1
hybrids. Offspring was subsequently back-crossed into a
C57BL/6J background.
mRNA isolation and RT-PCR. RNA was isolated from
collected neuroretinae homogenized by freeze and
thaw cycles using liquid nitrogen. RNA was isolated
using the AllPrep RNA/Protein Kit (Qiagen, Hilden,
Germany).
For cDNA synthesis, 80 ng of total retinal RNA was
reverse-transcribed using the PrimeScript cDNA Syn-
thesis Kit (Takara, Saint-Germain-en-Laye, France).
PCR amplification was performed using the Prime-
Script Polymerase (Takara, Saint-Germain-en-Laye,
France). The same primer pairs as for the initial screen-
ing (internal sonde iS) were used. Since the primers
were placed outside the repetitive region and the PCR
products were comparably small, we were able to gen-
erate sequencing data from gelpurified PCR products
(Seqlab, G€ottingen, Germany).
Western blot. Neuroretinae (n = 3) from 3 months old
wild type, mutant, and age matched Rpgrko23 animals
were harvested and lysed using the RIPA (radioimmu-
noprecipitation assay) buffer. Fifty micrograms of total
protein extract was analyzed by SDS-PAGE and
immunoblotting using the RPGRORF15 antibody, which
identifies an epitope in the C-terminal region of the
ORF15 frame, as described.8 The antibody was kindly
provided by Anand Swaroop (NEI).
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Fig 1. Generation of the mouse model. (A) Scheme of the recombination strategy of the targeting vector and the genomic mouse DNA applied for
the generation of this mouse model. The locations of the mutational sites marked with asterisks and amplification sites for screening via PCR are
indicated by brackets. The “floxed” neomycin-cassette is deleted via cre-recombination from the genome. Inserted mutations are specified by 14.
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Immunofluorescence. Two different techniques were
used to prepare the retinal tissue.
(1)
Enucleated eyes were embedded unfixed in OCT
medium (optimal cutting temperature ¡20˚C, Reich-
ert Jung, Wetzlar, Germany) before preparing sec-
tions of 16 mm, which were subsequently fixed for
13 minutes at room temperature in 4% paraformalde-
hyde in 0.1 M phosphate buffered saline (PBS).
(2)
Eyecups were harvested and immediately fixed for
4570 minutes in 4% paraformaldehyde. Eyecups
were then cryo-protected in graded sucrose solutions.
Vertical sections (16 mm) were cut with a cryo-
microtome (SLEE Medical GmbH, Mainz, Ger-
many) and collected on Superfrost slides.
Slides were incubated over night at 4˚C with S1 and
S3 rabbit polyclonal RPGR antibodies, diluted 1:200, or
with a cocktail of rabbit polyclonal RPGR antibody and
acetylated tubulin antibody, diluted 1:300 and 1:5.000
respectively. Primary antibodies were diluted in PBS
containing 3% normal donkey serum (NDS) and 0.5%
Triton X-100: S1 and S3 rabbit polyclonal RPGR anti-
bodies were kindly provided by Dr. Tiansen Li (NEI).
Rabbit polyclonal RPGR-ORF15 antibody targeting the
C-terminal region of the ORF15 exon (see reference8 for
further information) was used as well. Monoclonal acety-
lated tubulin antibody was commercial (# T 6793,
Sigma-Aldrich, Darmstadt, Germany). After washing
with 0.1 M PBS, sections were incubated with Alexa-
Fluor488 donkey antirabbit (1:500) secondary antibody
(Molecular Probes, UK, Europe, #A21206) for 1.5 hours
at room temperature. Nuclei were stained by DAPI (1
mg/ml; Molecular Probes, UK, Europe, #D1306) during
incubation with secondary antibodies. For double immu-
nolabeling, the respective primary and secondary anti-
bodies were applied as a cocktail. Sections were
mounted with antifade medium (Aqua Poly/mounting
medium, Polysciences, #18606) and examined by laser
scanning confocal microscopy (Olympus FV10i, Ham-
burg, Germany; equipped with argon and HeNe lasers).
Retinal histology. Enucleated eyes were fixed in yel-
low fix solution (45% formaldehyde, 45% PBS, 8%
glutaraldehyde, and 2% picric acid) for 4 hours and
rinsed in PBS overnight. The retinae were then post-
fixed in 1% osmium tertoxide (2 hours) at pH 7.3,
dehydrated in graded ethanols, and embedded in the
EMbed-812 epoxy resin (all reagents from Science
Services, Munich, Germany; automated LYNX-Tissue
processor Leica, Bensheim, Germany). After 48 hours
of heat polymerization at 60˚C, semithin (0.5 mm) tis-
sue sections were obtained and stained with toluidine
blue. Pictures were taken with the Keyence BC8000
digital microscope (Keyence Inc, Japan).
Optical coherence tomography. The MICRON III
fundus camera was used with modular spectral domain
OCT technology (Phoenix Research Inc, CA), specifi-
cally developed for rodent applications (axial optical
resolution 3 mm), and B scans were averaged over 10
frames. At least 3 animals per time point were analyzed
over time. Total retina and outer nuclear layer (ONL)
thickness were measured over the entire length of the
scan (excluding the papilla in central scans) using the
Insight OCT segmentation software (Phoenix Research
Inc, Calif). Mean thickness and standard deviation was
calculated from each group of animals. Significance
was tested using a student t test with P < 0.05.
Electroretinography. Animals were anaesthetised by
injection of xylazine (9 mg/kg body weight; 2% Xyla-
zin, Ceva Sante Animale, Libourne, France) and keta-
mine (90 mg/kg body weight; 10% Ketavet #
9089.01.00, Bela-Pharm GmbH & Co. KG, Vechta,
Germany). Full-field stimulation was performed using
an Espion E3 Electrophysiology system with a Color-
Dome full-field Desktop Ganzfeld stimulator (Diag-
nosys LLC, Lowell).
Mice were dark-adapted overnight and anesthetized
under dim red light. Pupils were dilated with Tropica-
mide (1%, # 23.0311.03, Mydriaticum Stulln, Pharma
Stulln, Stulln, Germany). For local anaesthesia Propar-
akain-Pos (0.5%, Ursapharm, Saarbr€ucken, Germany)
was used in addition to Methocel (2%, # 421503,
OmniVision GmbH, Puchheim, Germany) application
to keep the cornea moist. A gold-wire ring electrode
was used as recording electrode, and subcutaneous
below the scheme. The genomic modification was verified by sequencing an internal sonde (iS) and an external sonde (eS) (B) Confirmation of intro-
duced sequence modifications by Sanger sequencing. An XbaI site was introduced as a silent substitution of a T by a C. The pathologic frame shift
mutation was generated by deleting an A (represented by a missing T, because the sequencing was done on the reverse strand). The I-SceI site was
introduced downstream of the reading frame in the mutant animal by exchanging 6 nucleotides. (C) Theoretical length and amino acid repeats in the
RPGR-ORF15 protein. The EEGEGE repeats are changed to a ERKXGR repeat profile (where X stands for an K, R, or M amino acid), and the full
length protein is supposed to be shorter compared to the wild type. DNA, deoxyribonucleic acid; PCR, polymerase chain reaction; RPGR, retinitis
pigmentosa GTPase regulator; tx, heterozygous; ty, hemizygous mutant (mut); xx = homozygous wild type (wt).
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needle electrodes as reference (between the ears) and
ground (tail) electrode. Body temperature was main-
tained at 37˚C using a heating pad.
Electroretinographies (ERGs) were performed as
previously described.24 Briefly, single flash recordings
were obtained both under dark-adapted (scotopic) and
light-adapted (photopic) conditions. Light adaption
was performed with a background illumination of 30
cd/m2 presented for 10 min. White stimuli were pre-
sented with increasing intensities, reaching from 104
cd s/m2 to 25 cd s/m2, divided into 10 steps of 0.5 and
1 log cd s/m2. Twelve to fifteen responses were aver-
aged with an interstimulus interval of 5 seconds or 17
seconds (for 1, 3, 10, and 25 cd s/m2).
Significance was tested using a student t test with P
< 0.05.
Targeting of the I-SceI site in vitro. The ORF15 exon
from the targeting vector that was used to generate the
mouse model was cloned into the pcDNA 3.1 (-) vector,
under the control of a cytomegalovirus early enhancer
promoter (CMV) promotor (Invitrogen/ThermoFisher
SCIENTIFIC). Four micrograms of the vector was line-
arized with EcoRI and then transfected into HEK293
cells in a 6-well plate as mentioned earlier. Fourty-eight
hours following the transfection, 0.5 mg/mL Geneticin
(Life Technologies) was added to the medium for selec-
tion. Surviving cell foci were picked and transferred to
24 well plates. The selection process was repeated twice.
The integration was analyzed using automated DNA
sequencing by Sanger’s methods.
I-SceI cDNA sequence was cloned into a bicistronic
expression cassette together with the GFP cDNA sepa-
rated by a T2A linker sequence under the control of a
CMV promoter. After transfection of the expression
plasmid into the HEK293¡mORF15 cell line, GFP posi-
tive cells were sorted 72 hours later by Fluorescent
Activated Cell Sorting (FACS) and DSB repair events
were analyzed using the T7 SURVEYOR assay (NHEJ
events).
Targeting of the I-SceI site in vivo. The expression cas-
sette CMV.I-SceI-T2A-GFP (the same as for the in
vitro experiment) was cloned into an SSV9 vector.
AAV2/5.CMV.I-SceI-T2A-GFP was produced in the
Vector Core at the University Hospital of Nantes
(http://www.vectors.nantes.inserm.fr) and the titer was
determined by dot blot and expressed as vector
genomes (vg)/mL. Viral preparation was manufactured
using the HEK293 cell transfection method and puri-
fied by cesium chloride density gradients followed by
extensive dialysis against PBS.
AAV2/8.RK.I-SceI-T2A-GFP was produced in the
lab of John Neidhardt, Oldenburg. Here, the CMV pro-
moter was replaced by the Rhodopsin kinase (RK) pro-
moter within the SSV9 vector plasmid. Viral
preparation was manufactured using the HEK293 cell
transfection method and purified by ultracentrifugation
on iodixanol gradient. Iodixanol gradient was
exchanged by PBS and the titer was determined by
quantitative PCR.
For transfer of AAV vectors into the subretinal
space, 2-month-old mice (B6J.Sv129-Rpgrtm1Sti) were
anesthetized and pupils dilated as for the ERG meas-
urements. A syringe (Hamilton, Reno, NV) with a
blunt, GA34 12 mm needle (# 207434, Hamilton Com-
pany) was inserted tangentially through the conjunctiva
and sclera and placed under visual control in the nasal
half of the retina into the subretinal space (ie, between
the retina and retinal pigment epithelium). One micro-
liter vector suspension was injected to produce a bul-
lous retinal detachment. Correct bleb formation was
verified by OCT imaging immediately following the
procedure.
Two months after injection, GFP expression was
verified in vivo using the MICRON III camera (Phoe-
nix Research lab). Animals were subsequently eutha-
nized and the retina was dissociated. Dissociation was
performed using the Papain-kit (Worthington Bio-
chemical Corp) according to the protocol of the manu-
facturer with slight modifications. Briefly, retinae were
kept for 90 minutes in Hanks balanced salt solution
buffer at 37˚C before being digested with Papain for 45
minutes at 37˚C under constant shaking. DNAse diges-
tion was performed in Earle’s balanced salt solution
together with Ocomucoid and bovine serum albumin,
and cells resuspended after centrifugation in PBS.
Dissociated cells were sorted by FACS according to
their GFP expression profile. Cells from the nonin-
jected retinae were also FACS sorted according to their
size and granulation (photoreceptor enrichment). DSB
repair events were analyzed using the T7 SURVEYOR
assay (NHEJ events).
RESULTS
Generation of the B6J.Sv129-Rpgrtm1Sti mouse model. For the generation
of the mouse model, a targeting vector containing a pathological
point mutation (c.2793delA) was used for homologous recombina-
tion into the Rpgr locus of murine ES cells (C57BL/6/129sv hybrid
cells)22 (Fig 1, A, mutation 2). To obtain an extended altered amino
acid chain caused by the frame-shift mutation, the conditioned forma-
tion of a premature stop codon was prevented by introduction of an
additional single base substitution (c.3071subT-A) (Fig 1, A, muta-
tions 3). Furthermore, an XbaI restriction site (silent mutation, no
change of encoded amino acid) was introduced for later screening
purposes (c.2650subT-C) (Fig 1, A, mutations 1). Since the newly
generated mouse model was created to be used for the development
of therapeutic strategies based on genome editing, a recognition site
for the I-SceI homing-endonuclease was integrated into the genome
downstream of the Orf15 stop codon in the mutant sequence (Fig 1,
A, mutation 4).
Translational Research
62 Schlegel et al January 2019
Successfully recombined stem cells were implanted into surrogate
BALB/c mother mice and offspring was screened for chimeric events
and sequence changes on the X chromosome. F1 offspring carrying
the targeted mutations on the X chromosome was crossed with Cre-
deleter mice to remove the neomycine selection cassette and further
breeding was performed into the C57BL/6J background. Sequence
changes were verified at the genomic level through Sanger sequenc-
ing during the breeding process (Fig 1, B). The entire sequence of the
putative mutant full length cDNA is provided in the Supplementary
file 1.
The resulting mutant protein is considered to contain RK repeats
instead of EG repeats and is slightly shorter compared to the wild
type protein (Fig 1, C). The amino acid sequence of the putative full
length RPGRORF15 isoform is shown in Supplementary file 2.
Expression of the mutant allele and protein in the mouse model. Expres-
sion of the targeted RpgrOrf15 allele was verified on RNA and protein
level. Messenger RNA (mRNA) from neuroretinae of mutant and
wild type animals was used as a template for cDNA synthesis via
reverse transcription. A PCR product of 500bp in size was generated
from the region containing the pathological mutation (2793delA)
(Fig 2, A), and was sequenced to verify the alteration of the sequence
(Fig 2, B).
Translation of mRNA into protein was verified on whole retina
extracts from animals at the age of 3 months using an antibody that
recognizes an epitope in the C-terminal part of the ORF15 exon, thus
allowing to recognize the RPGRORF15 isoform specifically (Fig 2, C).
As a control, protein from age matched Rpgrko mouse retinae was
used.23 Bands with sizes below and above 150 kD were detected in
the wild type retina, indicating the presence of several ORF15 var-
iants with alternative amounts of the ORF15 acidic domain. In con-
trast, in the mutant retina, the total amount of RPGR protein was
lower, and some of the isoforms appeared to be absent from the blot.
The largest band, widely considered to be the RPGR-ORF15 full
length band was visible in both samples, with the size in the mutant
sample being slightly higher, potentially associated with the lower
amount of acidic amino acids being present in this protein.
Expression and localization of the different RPGR isoforms was
subsequently analyzed on retinal frozen sections of 3-month-old ani-
mals (Fig 3). First, we employed the same ORF15 specific antibody
as was used in the Western blot together with an antibody staining
acetylated tubulin, which marks the CC (Fig 3, A and B). The differ-
ence in immunolabeled RPGR-ORF15 protein between wild type and
mutant retina was obvious. In the wild type retina, RPGRORF15
immunoreactivity (green color) was of rod-like shape with brighter
small spots (Fig 3, A, zoomed inserts). It was visible at the OS-axo-
neme side of almost every single Actub immunoreactive CC (red
color). At the distal end of the immunolabeled CC, a small area of
co-localization of RPGRORF15 and Actub was visible (orange color).
Similarly, albeit more spot-like, staining of RPGRORF15 was detect-
able at the OS-axoneme side of the Actub immunoreactive CC in the
mutant retina, the majority of it being correctly localized to the CC
but with reduced immunoreactivity (zoomed inserts). In addition,
exceptionally long rod-like accumulations of immuno-labeled
RPGRORF15 have been observed on the distal side of the CC, more
frequently in the mutant than wild type retina. Since background sig-
nal was observed in both wild type and mutant outer retina, mislocali-
zation of RPGRORF15 was not assumed.
To further characterize the expression and localization of both iso-
forms, we also used S1 and S3 antibodies that have been widely used
to stain RPGR proteins in the retina. The S1 antibody, which recog-
nizes both the RPGRORF15 as well as the RPGRconst variant, detected
RPGR protein in both wild type and mutant animals at the IS-side of
the CC co-localizing with the Actub antibody (Fig 3, C and D). The
reduced RPGRORF15+const immunoreactivity in mutant animals was
due to the more spot-like appearance (Fig 3, D).
Staining with the antibody S3, which recognizes only the
RPGRconst variant, revealed clear immunolabeling in the wild type
and mutant retina co-localizing with the Actub antibody at the IS-
side of the CC (Fig 3, E and F). In the mutant retina RPGRconst stain-
ing had a bright and rod-like appearance and was visible in every
Actub immunoreactive CC. In comparison to the wild type retina, it
appeared to be slightly more intense. The spot-like appearance of
RPGRconst immunoreactivity in the wild type retina resulted in a less
prominent fluorescence than RPGRORF15+const immunolabeling (Fig
3, C).
In summary, these data demonstrate the expression and translation
of mutant RPGRORF15 mRNA. The RPGRconst isoform is unaltered in
its location but seems to be potentially upregulated when detected by
Fig 2. Verification of transgene expression in the retina. (A) For the verification of the expression of the transgene in the retina, mRNA samples
from retinal extracts were transcribed via reverse transcription and subsequently amplified via PCR. As controls mRNA samples were used as PCR
template to check them for contaminations of genomic DNA, which could lead to inaccurate test results. (B) PCR products were checked for the
mutational sites using direct Sanger sequencing. The comparison of the histograms shows the pathological point mutation (an adenine deletion
sequenced on the complementary strand and therefore displayed as thymine deletion.) (C) Western blot of retinal extracts (»100 mg) from wild type
(wt) and mutant (ty), and as negative control from Rpgrko (KO) mice at the age of 3 months probed with the RPGRORF15 specific antibody. Immuno-
blot of the same samples with anti-b-tubulin antibody served as loading control. DNA, deoxyribonucleic acid; PCR, polymerase chain reaction;
RPGR, retinitis pigmentosa GTPase regulator.
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the RPGRconst antibody. The 2 RPGRORF15 antibodies applied in this
study to detect the RPGRORF15 protein revealed different subciliary
localizations in both the wild type and mutant retina. While this
might be due to technical reasons with the postfixation technique, it
can also be associated with different epitopes recognized in different
RPGRORF15 isoforms as seen in our immune blot results (Fig 2, C).
Further studies are ongoing to shed more light on this observation.
Significant reduction of retinal layer thickness starting at 9 months. Ini-
tially, the retina was analyzed at young age (36 months) and old age
(1518 months) for changes to the gross retinal morphology (Fig 4,
AD). In young mutant retinae, the gross morphology was similar to
healthy retinae, with the exception that the outer segments looked
slightly disorganized (Fig 4, A and B). Older mutant retinae displayed
significant structural changes compared to healthy retinae, including a
loss of column like organization of the nuclei, and outer segment
destruction (Fig 4, C and D). No morphologic changes in the inner
nuclear layers (ganglion cell layer) were observed in mutant animals
(data not shown). Quantification of photoreceptor cell nuclei showed a
slight loss of nuclei at early ages (36 months) in mutant retinae,
which increased over time and aggravates at late ages (1821
months), where only about 50% of nuclei were left (Fig 4, E).
In order to monitor photoreceptor degeneration over the entire
lifetime of the animals, we performed in vivo imaging of the retina
using OCT (Fig 5). Retinae were examined starting at 3 months up to
24 months of age every 3 months in the center and midperiphery
(5 disk diameter distance; Fig 5, A and B). From the earliest time
point onwards (even at 1 month, data not shown), the outer retinal
bands, which can be nicely seen in wild type retinae, were not
Fig 3. RPGR protein localization in the retina. (A, B) 16 mm sections of wild type (wt) and mutant (mut) animals at 3 months of age double immu-
nostained with the RPGRORF15 specific antibody recognizing the C-terminal part of the ORF15 region8 and the monoclonal acetylated tubulin anti-
body (Actub), a marker for the CC. Nuclei were stained using DAPI (blue). Low levels of background staining is visible in the inner segment area.
RPGRORF15 (green) is visible at OS-axoneme side of the Actub immunoreactive CC (red). Inserts in A and B are zoomed in two-fold (zoom col-
umn). Individual immuno-labeled CC are zoomed in further (2-fold; insets within the zoom column). (A) A small area of co-localization of
RPGRORF15 and AcTub was visible at the OS-axoneme side of the Actub immunoreactive CC (orange color). (B) RPGRORF15 immunoreactivity
appears reduced and more spot-like but correctly localized to the CC. In addition, exceptionally long rod-like accumulations of immunolabeled
RPGRORF15 can be observed on the OS-axoneme side of the CC, more frequently in the mut than wt retina. Some background signal was observed
in both wt and mut outer retina with the RPGRORF15 antibody. (CF) 16mm sections of wild type and mutant animals at 3 months of age were
stained with either S1 (C, D) or S3 (E, F) antibody, recognizing both the RPGRORF15 and the RPGRconst isoform, or only RPGRconst, respectively.
Inserts in all images show a two-fold magnified region with co-localization of the RPGR antibody with the Actub antibody (zoom column). Individ-
ual immuno-labeled CC are zoomed in further (two-fold; inserts within the zoom column). (C) In wt retina RPGRORF15+const immunoreactivity
(green) has a rod-like shape at the IS-axoneme side of the Actub immunoreactive CC (red). (D) In mut retina RPGRORF15+const immunoreactivity
appears more spot-like and therefore reduced. (E) In wt retina RPGRconst immunoreactivity shows spot-like appearance (F) In the mut retina
RPGRconst staining has a bright and rod-like appearance and is visible in every Actub immunoreactive CC. Therefore, RPGRconst immunoreactivity
appears to be up-regulated in comparison to the wt retina. Compared to the RPGRORF15 antibody (A,B) the background signal of the RPGRORF15
+const and RPGRconst immunostaining is very little in both wt and mut ONL retina. In mut retina RPGRcons showed almost no background labeling at
all. CC: connecting cilium; IS: inner segments; ONL: outer nuclear layer; OS: outer segments; RPE: retinal pigmented epithelium; RPGR, retinitis
pigmentosa GTPase regulator; Scale bars: 20 mm in AF; 10 mm in all zoom columns. (Color version of figure is available online.)
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Fig 4. Analysis of the retinal morphology. Semithin sections reveal morphologic alterations in the retinae of mutant mice. (A, B) Retina of a wild
type animal at 3 and 18 months of age. (C, D) Retina of mutant animals at 3 and 18 months of age. (E) For the quantification of photoreceptor nuclei
the number of nuclei in a section of 100 mm was counted at defined distances from the optic nerve head (n = 2 animals per group). Standard devia-
tions are shown. INL: inner nuclear layer; IS: inner segments; ONL: outer nuclear layer; OPL: outer plexiform layer; OS: outer segments; RPE: reti-
nal pigmented epithelium.
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Fig 5. In vivo imaging of the retina using optical coherence tomography (OCT). (A) Retina of wild type and mutant animals were examined in the
central or peripheral part (5 disk diameter distance) of the retina. The white brackets in the B scans indicate the outer retinal bands region. The green
or black line in the fundus photographs highlights the area where the OCT scans was obtained. Scale bar: 50 mm. (B) Timeline of OCTs from the
peripheral scans from wild type animals (3 and 15 months) and from mut at 3, 6, 9, 12, 15, 18, 21, and 24 months. (C) Entire retina and ONL thick-
ness in wild type and mutant animals were quantified between 3 and 24 months of age (n = 4 animals per group). CH: choroid; ELM: external limit-
ing membrane; GCL: ganglion cell layer; INL: inner nuclear layer; IPL: inner plexiforme layer; IS: inner segments; ISe: inner segments ellipsoid;
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discernable in the mutant retina (Fig 5, A, white brackets in OCT
scans). These findings confirm the observation of outer segment dis-
organization in mutant animals as seen in Fig 4, B and represent an
early biomarker for morphologic changes in the retina.
The thickness measurements of the entire retina as well as ONL
alone show a progressive thinning of the layers, which becomes sig-
nificant at the age of 9 months (Fig 5, B and C). Both, entire retina
and ONL thickness in the center as well as the periphery are initially
slightly thinner in mutant retina with a first decline at 9 month fol-
lowed by a plateau phase until 15 months. Beyond that age, entire ret-
ina and ONL thickness rapidly decline until only minimal ONL
thickness is left at 24 months of age and the entire retina thickness is
only 50% of normal.
Significant reduction of functional changes starting at 12 months. Retinal
function was analyzed using standard ERG recordings at different
ages between 1 and 21 months (Fig 6). In the dark-adapted ERG,
responses show progressing decrease of the a-wave amplitude, start-
ing to be significant at the age of 12 months (Fig 6, A, B, and H). At
21 months, only about 35% of normal a-wave amplitudes were
reached in mutant animals. B-wave amplitudes also decrease progres-
sively starting at 12 months of age (Fig 6, C). The b/a-wave ratio
remained unchanged at about 2, indicating a progressive degenera-
tion of photoreceptors and second order neurons over time (data not
shown). Albeit the amplitudes were decreased, characteristic wave-
forms remained in a-waves as well as in b-waves including oscil-
latory potentials (Fig 6, A and B). Interestingly, a-wave latency was
increased in older mutant animals compared to age matched control
mice (data not shown).
Under photopic conditions, b-wave amplitude was also slightly,
but not significantly decreased in mutant animals (Fig 6, D and E).
Photopic flicker responses were severely reduced in older animals
(1821 months) but not in young animals (36 months) (Fig 6, F
and G).
DNA repair at the I-SceI locus in vitro and in vivo. In order to perform a
proof of principle experiment demonstrating the possibility to edit the
genome at the I-SceI locus, we employed a HEK293 cell line contain-
ing the C-terminal part of the murine ORF15 exon (Fig 7, A). A vector
cassette containing the I-SceI and GFP cDNA linked by a T2A peptide
under the control of a CMV promoter was used (Fig 7, B). Upon trans-
fection, we subsequently enriched the transfected cell population to be
analyzed by cell sorting of GFP positive cells (FACS). Upon enrich-
ment, the surveyor assay (T7E1) was performed to visualize NHEJ
events, which were at relatively high levels in the enriched cell popula-
tion (Fig 7, C). Since nonenriched samples lower levels of NHEJ
events, this method to isolate endonuclease expressing cells is impor-
tant to obtain larger number of DNA editing events.
Upon successful proof of concept in in vitro experiments, we fur-
ther evaluated the possibility to use I-SceI mediated genome editing at
the ORF15 locus in vivo. One microliter each of AAV vectors
(titer = 3£ 1011 vg/mL) containing the I-SceI-T2A-GFP expression
cassette either under the control of the ubiquitous CMV promoter
(AAV2/5) or the photoreceptor specific RK promoter (AAV2/8) was
subretinally administered into the Rpgrtm1Sti mouse retinae at 8 weeks
of age (Fig 8, A). Two months later, GFP expression was verified by
in vivo fluorescent imaging (Fig 8, B), and retinal cells were dissoci-
ated and FACS enriched for GFP expression (Fig 8, C). Noninjected
eyes were sorted for size and granulation. The enriched cells were sub-
jected to the surveyor assay (T7E1) showing evidence of NHEJ activ-
ity at the target locus only in the injected eyes. Control vectors
containing exclusively the GFP cDNA under the control of a CMV
promoter were also injected into control animals, and did not show
any sign of NHEJ events in the surveyor assay (data not shown).
DISCUSSION
In this study, we describe a new mouse model for
human XLRP, which contains a single pathologic point
mutation in the Rpgr-Orf15, a genetic alteration found
frequently in human patients. We observed expression
and limited translation of the mutant Rpgr-Orf15 tran-
script, and a slowly progressive degeneration starting
at the photoreceptor level at about 9 months of age,
both morphologically and functionally. Furthermore,
we show for the first time in vivo genome editing at the
Rpgr-ORF15 locus by using the I-SceI endonuclease.
The uniqueness of the presented mouse model lies in
the presence of an I-SceI site close to the Rpgr gene
locus, which can be used in subsequent experiments to
study the efficacy of genome editing approaches based
on homing endonucleases (HE) or other systems. Since
the I-SceI endonuclease has a longstanding history in
showing high efficacy and low toxicity in eukaryotic
cells, this nuclease can now be used as a reference stan-
dard for studies using the current state of the art RNA
based endonuclease systems (ie, CRISPR-Cas). Recent
developments in the research for HE point even toward
programmable variants, making our model even more
relevant for future studies. Furthermore, due to its
small size, HE including I-SceI is the single nuclease
class that can be packaged into one single AAV vector
together with the template DNA, which allows us to
study the importance of using a 1-vector system com-
pared to a 2-vector system, a question that is currently
unanswered due to the lack of useful models and nucle-
ases. In vivo studies addressing this question are cur-
rently ongoing.
Even though the Rpgr-ORF15 sequence is optimal
for genetic modifications due to its highly repetitive
nature, replacement of the entire exon by homology-
directed repair or microhomology-mediated end-join-
ing could be envisaged as one treatment approach for a
large number of patients with different mutations
within that exon. Therefore, targeting this exon by HE
or other systems in a relevant animal model is of high
interest to the scientific community.
In our mouse model, we observed protein translation
from the mutant RpgrOrf15 transcript. This is in slight
contrast to the situation observed in the rd9 mouse
model, which contains a 32 bp deletion in the ORF15
ONL: outer nuclear layer; OPL: outer plexiforme layer; OS: outer segments; RPE: retinal pigmented epithelium; RNFL: retinal nerve fiber layer; * P
< 0.05. (Color version of figure is available online.)
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region leading to a frame shift similar to our model and
which shows only residual levels of the mutant protein
in western blot and immunofluorescence assays.25 Fur-
thermore, normal amounts of the RPGRconst isoform
were produced and are correctly localized in the CC in
our mouse model, while no S3 antibody staining was
detected in the rd9 mouse.25 A possible reason for this
difference could be a differential regulation of the
Fig 6. Functional examination using electroretinography (ERG). (A) Representative scotopic single flash
recordings of young (36 months of age) and old (1821 months of age) wild type (wt) and mutant (mut) ani-
mals. (B) Scotopic a-wave amplitudes separated for each flash intensity for wild type (wt) and mutant (mut) ani-
mals between 3 and 21 months of age (n =4 animals per time point). (C) Scotopic a-wave amplitudes separated
for each flash intensity for wild type (wt) and mutant (mut) animals between 3 and 21 months of age (n = 4 ani-
mals per time point). (D) Representative photopic single flash recordings of young (36 months of age) and old
(1821 months of age) wild type (wt) and mutant (mut) animals. (E) Photopic a-wave amplitudes separated for
each flash intensity for wild type (wt) and mutant (mut) animals between 3 and 21 months of age (n = 4 animals
per time point). (F) Representative photopic flicker responses of young (36 months of age) and old (1821
months of age) wild type (wt) and mutant (mut) animals. (G) Correlation of photopic flicker amplitude and
flicker frequency in wild type and mutant animals at young (36 months) and old (1821 months) age. (H) Cor-
relation of scotopic a-wave amplitudes with age. Differences between wild type and mutant animals start to be
significant at 12 months of age. * P < 0.05.
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RPGRconst isoform in both disease models, a mecha-
nism already seen in selective KO models of either
Rpgrconst or RpgrOrf15.26 Further studies to decipher
this potential mechanism are currently ongoing.
We observed thinning of the ONL and reduction of
photoreceptor nuclei at later stages of the disease. In
the context of a therapeutic setting, such late reductions
of photoreceptor cells and function may not be advan-
tageous, since readout parameter following treatment
would become significant only at late stages.14 On the
other hand, this long-lasting presence of photoreceptors
generates potentially a long therapeutic window. More
importantly, the early alterations to the photoreceptor
morphology, that is, the absence of the outer retinal
bands on OCT scans early in the disease process, repre-
sent a useful readout parameter to study treatment out-
come at an early age.27
ONL thinning has already been shown for other
Rpgr mouse models, for example, in the rd9 mutant
mice becoming clear and significant around 12 months
Fig 7. Genome editing at the I-SceI site in vitro. (A) Scheme of the generation of the cell line HEK293¡mORF15
by cloning the mutant RPGR-ORF15 region into the HEK293 cell line under the control of a CMV promoter.
Stars indicate the point mutations integrated into the ORF15 sequence. (B) The vector plasmid contains the I-
SceI cDNA linked with the GFP reporter gene by a T2A linker und the control of a CMV promoter, thus allow-
ing production of equal amounts of protein. Microscopy image shows the green fluorescent cells after transfec-
tion. FACS data show the enrichment of the GFP positive cell population. (C) Visualization of the DNA repair
events following transfection of the cell line with the plasmid vector and subsequent enrichment of the GFP pos-
itive cells. T7 surveyor assay demonstrates NHEJ activity at the target site in the GFP enriched cell population
and to a lower extend in the transfected cells without GFP enrichment. "+" and "¡" refers to whether FACS
enrichment, I-sceI expression and T7 endonuclease digestion took place or not.
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of age.25 The Rpgr knock-out mouse model developed
by Hong et al23 also showed a thinning of the photore-
ceptor nuclear layer with a loss of 2 rows of nuclei on
average by the age of 6 months, an observation that
was also reported by other groups.28,29 These findings
suggest that frame shift mutations in the Orf15 (like
the ones occurring in the rd9 model and the model pre-
sented here) lead to milder forms of degeneration com-
pared to knock-out mutations, which may be related to
a residual function of the altered protein.
Concerning the function of the photoreceptors, ERG
amplitudes in our model are reduced in scotopic
a-wave as well as b-wave, starting at the age of 12
months, coinciding with the start of photoreceptor
nuclear cell loss. Photopic flicker responses are simi-
larly reduced in older animals. These observations
indicate that both types of photoreceptors, rods and
cones are involved in the pathology. The impact of
aging on function is relatively small, since age-
matched wild type animals only show a slight reduc-
tion of the measured amplitudes. Similarly, functional
analysis showed reduced amplitudes for all known
Rpgr mouse models at later stages of the dis-
ease.25,23,28,30,31 Similar to our model, the rd9 model
shows a moderate but constant reduction of a-wave as
well as b-wave amplitudes until the age of 24
months.25 The knock-out mouse model by Hong et al
shows reduced a-wave amplitudes for rods as well as
for cones at the age of 6 months,23 while the model
established by Brunner et al shows only a mild reduc-
tion of the scotopic a-wave from the age of 3 months
onwards and no alteration of the scotopic b-wave.28
The pathologies observed in our model or in the pub-
lished rd9 mouse are less severe than those observed in
human patients. One base pair frame shifts with long
C-terminal protein chain alteration seem to be reason
Fig 8. Genome editing at the I-SceI site in vivo. (A) The two AAV vector constructs are depicted. The AAV2/5
vector contained an expression cassette in which I-SceI and GFP, linked by a T2A linker, were under the control
of a CMV promoter, thus allowing transgene expression in all transduced cells. The AAV2/8 vector contained
an expression cassette in which I-SceI and GFP were under the control of a Rhodopsin kinase (RK) promoter,
which ensures photoreceptor specific transgene expression. (B) In vivo fluorescence image from transduced ret-
ina showing the GFP expression in the injected area. onh: optic nerve head; bv: blood vessel. (C) FACS data
showing the enrichment of the GFP positive cell population. (D) DNA repair events following AAV mediated I-
SceI gene transfer and subsequent enrichment of the GFP positive cells resulted in measurable NHEJ activity in
both injected eyes, while control eyes did not reveal such activity. Positive control experiment was the in vitro
experiment described in Fig 7. "+" and "¡" refers to whether FACS enrichment, I-sceI expression and T7 endo-
nuclease digestion took place or not. DNA, deoxyribonucleic acid; FACS, fluorescent activated cell sorting;
NHEJ, nonhomologous end-joining.
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for the most severe phenotypes in humans, but only a
mild phenotype in mice (this study).25 Recent in vivo
analysis of human retinae with SD OCT technology
revealed early ONL thinning outside the fovea despite
the presence of identifiable ISe (inner segment retinoid)
and OS structures,5 which was also observed in other
studies.32,33 In contrast, the murine ISe and OS struc-
tures, which can be distinguished in wild type mice, are
not visible in mutant retinae. This has also been
observed in the knock-out mouse generated by Huang et
al.29 Since current understanding of functional correlates
identifies ISe as a valid morphologic indicator of func-
tional photoreceptors in OCT scans of humans, this is
not the case for murine OCT scans. In young affected
animals of our model, ERG recordings are unchanged,
yet the ISe band is not detectable from the beginning.
In summary, the newly generated mouse model dis-
plays a degenerative phenotype with thinning of retinal
layers starting at 9 months and loss of photoreceptor
function beginning at 12 months of age, indicating the
activation of a similar or at least closely related patho-
logic pathway like in human patients. Therefore, this
model is an eligible model for the development of gene-
therapeutic applications in the future. In addition, it may
help to gain further insight into the pathological mecha-
nisms involved in retinal degeneration and the expression
pattern of mutant Rpgr-Orf15. Moreover, the influence of
point mutations in the ORF15 repetitive region on
expression and splicing of the mRNA, as well as the bio-
chemical reason for the toxicity of emerging proteins
could be addressed by the model in further experiments.
Finally, the use of this model to study genome editing in
the degenerating retina in vivo using all nuclease classes
currently available renders the model very important.
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